Clinical trials: sponsored by UNC Lineberger Comprehensive Cancer Center
Breast Screening
Novel MRI Sequence MR Fingerprinting in Breast MRI Feasibility Study
The purpose of this study is to evaluate potential clinical efficacy of a novel magnetic resonance imaging (MRI) approach, MR fingerprinting, capable of providing quantitative measures of important tissue properties, which could…
- Trial name
- NCT03846947
- Testing
- MR Fingerprinting
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants
The purpose of this research study is to see if olanzapine helps to prevent nausea and/or vomiting (throwing up) when it is added to other medicines in subjects having stem cell transplants.
- Trial name
- NCT04535141
- Testing
- Olanzapine 5 MG
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cognitive Decline, Chemo-brain
Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
Purpose: To conduct a one-arm phase II trial to: (1) compare changes in pre- to post-chemotherapy cognitive function in a cohort of patients with breast cancer receiving memantine to historical controls; (2) examine how…
- Trial name
- NCT04033419
- Testing
- Memantine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Tobacco Use, Cigarette Use
Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco use is the leading preventable cause of cancer and cancer deaths in the US. While most (69%) smokers want to quit, only 6% succeed in doing so each year.
- Trial name
- NCT04974489
- Testing
- Emotion-based messages about the harm of VLNC, Continued-harm-framed messages about the harm of VLNC, Myth-refuting messages about the harm of VLNC
- Where
- United States
- Volunteers
- 1,153 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis
This is a study that will evaluate the utility of a scatter reduction technique in reducing dose and increasing the sensitivity of stationary digital chest tomosynthesis (s-DCT) in the detection of lung lesions.
- Trial name
- NCT04076696
- Testing
- Scatter corrected s-DCT
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
HPV Vaccine, Provider Communication Practices
Mobile Coaching to Improve HPV Vaccine Delivery
The purpose of this study is to examine the feasibility of using Checkup Coach, a mobile coaching intervention, to improve the way that primary care providers recommend HPV vaccination to adolescent patients and their parents.
- Conditions
- HPV Vaccine, Provider Communication Practices, Vaccine Recommendation Practices
- Trial name
- NCT05105711
- Testing
- QI coaching intervention
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel
The purpose of this research study is to test the effectiveness of three treatment arms that are designed to improve survival in patients with non-small cell lung cancer.
- Trial name
- NCT02684461
- Testing
- Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Signs and Symptoms
Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules
Purpose: The proposed research, if successfully implemented, will result in a low-dose, low-cost, and highly effective method for screening of lung cancer, leading to reduction of the lung cancer mortality rate.
- Trial name
- NCT02075320
- Testing
- Stationary Digital Chest Tomosynthesis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Signs and Symptoms
Academic-Industrial Partnership for Translation of Acoustic Angiography
Purpose: The primary objective of this single arm study is to compare the sensitivity and specificity of acoustic angiography with traditional b-mode ultrasound in the distinction of malignant versus benign breast lesions.
- Trial name
- NCT03544268
- Testing
- Acoustic Angiography, Definity
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Adult
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
The standard chemotherapy for Hodgkin lymphoma is called ABVD which is a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine).
- Trial name
- NCT01578967
- Testing
- Brentuximab vedotin, ABVD
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematopoietic Stem Cell Transplantation, Delirium
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
Purpose: To conduct a randomized controlled pilot study investigating the use of high dose intravenous (IV) thiamine to prevent delirium and mitigate the long-term effects of delirium, including health-related quality of life…
- Conditions
- Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
- Trial name
- NCT03263442
- Testing
- Thiamine, Normal saline
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Cancer
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
Overweight and obese endometrial cancer (EC) survivors at the University of North Carolina (UNC) at Chapel Hill will be approached for tailored feedback fitness intervention.
- Trial name
- MOVES (NCT03820024)
- Testing
- Tailored Feedback Messages
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Castration-resistant Prostate Cancer, Androgen Deprivation Therapy
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer…
- Trial name
- NCT03672396
- Testing
- Home-based exercise
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Malignant Pleural Effusion, Stage IV Metastatic Cancer
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
This is a Phase Ib/II clinical trial to evaluate the feasibility of administering talimogene laherparepvec into the intrapleural space of subjects with malignant pleural effusion through a pleurX catheter.
- Conditions
- Malignant Pleural Effusion, Stage IV Metastatic Cancer, Lung Cancer
- Trial name
- NCT03597009
- Testing
- Talimogene laherparepvec (TVEC), Nivolumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Sarcoma
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas.
- Trial name
- NCT03076333
- Testing
- PET/MR
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cigarette Smoking Behavior
Enhancing Source Credibility in Tobacco Regulatory Communications
This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial.
- Trial name
- NCT03339206
- Testing
- Constituent message with FDA and quitline, Constituent message without FDA and quitline, Littering message (Control)
- Where
- United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Cancer
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
- Trial name
- NCT01412229
- Testing
- Cetuximab, Nab-paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage III Melanoma, Stage IV Melanoma
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
This phase II study in 20 patients with BRAFV600E mutant, unresectable stage III/IV melanoma is designed to explore the mechanisms by which tumors acquire resistance to the combination of a BRAF inhibitor (dabrafenib) and MEK…
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
- Trial name
- NCT01726738
- Testing
- BRAF inhibitor dabrafenib and MEK inhibitor trametinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center